[Pharmacologic principles in the treatment of XXXX in the @entity235 and cat].

@entity1 @entity410 @entity3175 @entity235 @entity1092 @entity409 @entity1245 @entity3303 @entity109 @entity302 @entity8821 @entity3174 @entity468 @entity2049 @entity159 @entity2053
The pharmacokinetics of antiepileptic drugs used for the treatment of @entity1 @entity302 is reviewed for @entity235 and @entity468 . In @entity235 , especially @entity109 and @entity8821 must be regarded as useful drugs for chronic treatment on account of their elimination rate and bioavailability. @entity3174 , @entity2049 , @entity1092 and @entity1245 are eliminated so rapidly that a therapeutic value cannot be expected. In @entity468 , @entity3174 , @entity109 , @entity1092 and @entity3175 must be regarded as suited for chronic treatment, but there is a definite lack of clinical experience. @entity109 and @entity8821 are useful for treatment of @entity410 (grand mal) in @entity235 . The effect of @entity8821 depends mostly on its metabolite @entity109 . Since @entity8821 , given in high dosage for longer periods of time, gives rise to @entity409 , @entity109 is regarded as the drug of first choice. A @entity159 may be treated by i.v. injection of @entity3175 , @entity2053 , @entity3174 or @entity3303 . In @entity468 with grand mal, treatment with daily doses of about 1 mg/kg @entity3175 may be tried. It proved effective for longer time periods without development of tolerance. There is no reliable clinical experience with other drugs in this species.
